Featured ArticlesJDD HighlightsJDD WebinarsRosaceaThe LatestWebinars on Demand

Maintaining Control: Tools for Long-Term Treatment Success in Rosacea

By February 8, 2022February 13th, 2022No Comments

JDD Multimedia

Maintaining Control: Tools for Long-Term Treatment Success in Rosacea

Featuring Dr. Melinda Gooderham and Dr. Julie Harper

As part of Galderma’s overarching GEMME (Galderma Excellence in Multichannel Medical Education) program we would like to invite you to attend our “Maintaining control: Tools for Long-Term Treatment Success in Rosacea” webinar. This webinar will discuss optimizing outcomes with a focus on long-term management and the importance of patient adherence in rosacea patients and will bring you the latest data and insights from our expert faculty of international speakers.

Supported by


Dr. Melinda Gooderham
Dermatologist and Medical Director at the SKiN Centre for Dermatology
Assistant Professor at Queen’s University and Consultant Physician
Peterborough Regional Health Centre, Canada

Dr. Julie Harper
Dermatology and Skin Care Center of Birmingham
Alabama, USA

You May Also Like

What’s New in Topical Treatment for Actinic Keratosis

| CME Activities, JDD Webinars | No Comments
In this one-hour CME webinar, participants will learn the latest information on new topical therapeutic considerations for actinic keratosis, including the recently approved SrC kinase inhibitor. Upon completion of this…

Actinic Keratosis: Current Understanding of Pathophysiology and Therapeutic Targets

| CME Activities, JDD Webinars | No Comments
Join JDD for Part One of this two-part webinar series on "Advancing the Understanding of Actinic Keratosis: New Treatment Options and Strategies." In this continuing education activity, faculty will explore…

Re-examining the Optimal Use of Neuromodulators and the Changing Landscape: A Consensus Panel Update

| CME Activities | No Comments
1 CME CreditSince initial US Food and Drug Administration approval of botulinum toxin type A (BoNT-A) for aesthetic use in 2002, clinical evidence and experience with BoNT-A and understanding of…

Leave a Reply